The USA’s Institute for Clinical and Economic Review (ICER) today released its new “Launch Price and Access Report,” finding ...

South Korea’s Samsung Bioepis today released its Fourth Quarter 2025 Market Report, marking the eleventh edition of the ...

Elixion Biotech has emerged from stealth with a breakthrough that it claims could reshape early-stage drug discovery.

Research from GlobalData highlights the strength of Novartis' (NOVN: VX) position in IgA nephropathy (IgAN), following strong ...

Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...

Swiss pharma giant Roche today released financial results for the first nine months of 2025, showing that group sales grew by ...

US pharma major Pfizer (NYSE: PFE) has selected newly launched Expedition Medicines, a Flagship Pioneering company, as its ...

Florida, USA-based Summit Therapeutics announced that it has accepted offers from multiple leading biotech institutional and ...

Japanese pharma major Astellas Pharma announced that the US Food and Drug Administration (FDA) accepted for priority review a ...

A US-based clinical-stage biotech company developing therapies for neuropsychiatric disorders, such as social anxiety ...

Q3 2025 report reveals that the biotech industry witnessed a 70.9% increase in total venture financing deal value from $1.8 billion in second-quarter 2025 to $3.1 billion in third-quarter 2025.

US biotech Moderna (Nasdaq: MRNA) is discontinuing its once-promising vaccine for congenital cytomegalovirus (CMV) after the shot failed to prevent primary infection in healthy women during a Phase ...